vs
Side-by-side financial comparison of SenesTech, Inc. (SNES) and China SXT Pharmaceuticals, Inc. (SXTC). Click either name above to swap in a different company.
China SXT Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($829.5K vs $421.0K, roughly 2.0× SenesTech, Inc.). China SXT Pharmaceuticals, Inc. runs the higher net margin — -96.8% vs -428.5%, a 331.7% gap on every dollar of revenue. On growth, China SXT Pharmaceuticals, Inc. posted the faster year-over-year revenue change (0.0% vs -16.0%). SenesTech, Inc. produced more free cash flow last quarter ($-1.7M vs $-1.8M).
SenesTech, Inc. is an agricultural biotechnology life-sciences company, specializing in fertility management as a form of pest control. The company's primary product, ContraPest is designed to make brown and black rats infertile. SenesTech is headquartered in Phoenix, Arizona.
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the Chinese domestic market. It engages in the research, development, production and distribution of traditional Chinese medicine-based prescription drugs, over-the-counter medications, and nutritional health products, serving both clinical medical institutions and consumer health markets.
SNES vs SXTC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $421.0K | $829.5K |
| Net Profit | $-1.8M | $-802.6K |
| Gross Margin | 55.3% | 16.2% |
| Operating Margin | -446.8% | -76.9% |
| Net Margin | -428.5% | -96.8% |
| Revenue YoY | -16.0% | 0.0% |
| Net Profit YoY | -43.7% | 0.0% |
| EPS (diluted) | $0.48 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $421.0K | — | ||
| Q3 25 | $690.0K | $829.5K | ||
| Q2 25 | $625.0K | — | ||
| Q1 25 | $485.0K | — | ||
| Q4 24 | $501.0K | — | ||
| Q3 24 | $482.0K | $829.5K | ||
| Q2 24 | $459.0K | — | ||
| Q1 24 | $415.0K | — |
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-1.3M | $-802.6K | ||
| Q2 25 | $-1.6M | — | ||
| Q1 25 | $-1.7M | — | ||
| Q4 24 | $-1.3M | — | ||
| Q3 24 | $-1.5M | $-802.6K | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-1.8M | — |
| Q4 25 | 55.3% | — | ||
| Q3 25 | 62.8% | 16.2% | ||
| Q2 25 | 65.4% | — | ||
| Q1 25 | 64.5% | — | ||
| Q4 24 | 60.9% | — | ||
| Q3 24 | 65.4% | 16.2% | ||
| Q2 24 | 54.2% | — | ||
| Q1 24 | 32.5% | — |
| Q4 25 | -446.8% | — | ||
| Q3 25 | -195.2% | -76.9% | ||
| Q2 25 | -258.2% | — | ||
| Q1 25 | -342.9% | — | ||
| Q4 24 | -250.9% | — | ||
| Q3 24 | -321.0% | -76.9% | ||
| Q2 24 | -349.0% | — | ||
| Q1 24 | -444.1% | — |
| Q4 25 | -428.5% | — | ||
| Q3 25 | -188.1% | -96.8% | ||
| Q2 25 | -258.6% | — | ||
| Q1 25 | -343.3% | — | ||
| Q4 24 | -250.5% | — | ||
| Q3 24 | -313.9% | -96.8% | ||
| Q2 24 | -345.1% | — | ||
| Q1 24 | -441.4% | — |
| Q4 25 | $0.48 | — | ||
| Q3 25 | $-0.28 | — | ||
| Q2 25 | $-0.87 | — | ||
| Q1 25 | $-1.28 | — | ||
| Q4 24 | $-0.15 | — | ||
| Q3 24 | $-2.07 | $-0.25 | ||
| Q2 24 | $-3.08 | — | ||
| Q1 24 | $-3.56 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.6M | $18.1M |
| Total DebtLower is stronger | — | $105.0K |
| Stockholders' EquityBook value | $9.6M | $15.4M |
| Total Assets | $12.8M | $21.7M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.6M | — | ||
| Q3 25 | $10.2M | $18.1M | ||
| Q2 25 | $6.1M | — | ||
| Q1 25 | $1.7M | — | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $2.5M | $18.5M | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $105.0K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $952.3K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $9.6M | — | ||
| Q3 25 | $11.3M | $15.4M | ||
| Q2 25 | $7.0M | — | ||
| Q1 25 | $2.9M | — | ||
| Q4 24 | $2.5M | — | ||
| Q3 24 | $3.7M | $15.0M | ||
| Q2 24 | $3.1M | — | ||
| Q1 24 | $4.6M | — |
| Q4 25 | $12.8M | — | ||
| Q3 25 | $14.6M | $21.7M | ||
| Q2 25 | $10.4M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $3.3M | — | ||
| Q3 24 | $4.4M | $31.0M | ||
| Q2 24 | $4.0M | — | ||
| Q1 24 | $5.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-1.4M |
| Free Cash FlowOCF − Capex | $-1.7M | $-1.8M |
| FCF MarginFCF / Revenue | -398.3% | -216.2% |
| Capex IntensityCapex / Revenue | 3.1% | 4.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-5.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | — | ||
| Q3 25 | $-1.4M | $-1.4M | ||
| Q2 25 | $-1.1M | — | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-1.4M | $-1.4M | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-1.8M | — |
| Q4 25 | $-1.7M | — | ||
| Q3 25 | $-1.4M | $-1.8M | ||
| Q2 25 | $-1.2M | — | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-1.4M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-1.8M | — |
| Q4 25 | -398.3% | — | ||
| Q3 25 | -205.9% | -216.2% | ||
| Q2 25 | -191.5% | — | ||
| Q1 25 | -328.5% | — | ||
| Q4 24 | -246.1% | — | ||
| Q3 24 | -296.1% | — | ||
| Q2 24 | -354.2% | — | ||
| Q1 24 | -441.2% | — |
| Q4 25 | 3.1% | — | ||
| Q3 25 | 6.1% | 4.9% | ||
| Q2 25 | 7.5% | — | ||
| Q1 25 | 7.4% | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 5.8% | — | ||
| Q2 24 | 8.5% | — | ||
| Q1 24 | 0.5% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
